JP2022534402A5 - - Google Patents
Info
- Publication number
- JP2022534402A5 JP2022534402A5 JP2021570170A JP2021570170A JP2022534402A5 JP 2022534402 A5 JP2022534402 A5 JP 2022534402A5 JP 2021570170 A JP2021570170 A JP 2021570170A JP 2021570170 A JP2021570170 A JP 2021570170A JP 2022534402 A5 JP2022534402 A5 JP 2022534402A5
- Authority
- JP
- Japan
- Prior art keywords
- rnai construct
- construct according
- scap
- nucleotides
- antisense strand
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025176137A JP2026016500A (ja) | 2019-05-30 | 2025-10-20 | ＳＣＡＰ発現を阻害するためのＲＮＡｉコンストラクト及びその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962854433P | 2019-05-30 | 2019-05-30 | |
| US62/854,433 | 2019-05-30 | ||
| PCT/US2020/035545 WO2020243702A2 (en) | 2019-05-30 | 2020-06-01 | Rnai constructs for inhibiting scap expression and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025176137A Division JP2026016500A (ja) | 2019-05-30 | 2025-10-20 | ＳＣＡＰ発現を阻害するためのＲＮＡｉコンストラクト及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022534402A JP2022534402A (ja) | 2022-07-29 |
| JP2022534402A5 true JP2022534402A5 (enExample) | 2023-06-05 |
| JP7763104B2 JP7763104B2 (ja) | 2025-10-31 |
Family
ID=71833431
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021570170A Active JP7763104B2 (ja) | 2019-05-30 | 2020-06-01 | ＳＣＡＰ発現を阻害するためのＲＮＡｉコンストラクト及びその使用方法 |
| JP2025176137A Pending JP2026016500A (ja) | 2019-05-30 | 2025-10-20 | ＳＣＡＰ発現を阻害するためのＲＮＡｉコンストラクト及びその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025176137A Pending JP2026016500A (ja) | 2019-05-30 | 2025-10-20 | ＳＣＡＰ発現を阻害するためのＲＮＡｉコンストラクト及びその使用方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20220307022A1 (enExample) |
| EP (1) | EP3976786A2 (enExample) |
| JP (2) | JP7763104B2 (enExample) |
| KR (1) | KR20220016138A (enExample) |
| CN (2) | CN113924368B (enExample) |
| AR (1) | AR119061A1 (enExample) |
| AU (1) | AU2020284254A1 (enExample) |
| BR (1) | BR112021024080A2 (enExample) |
| CA (1) | CA3141902A1 (enExample) |
| CL (2) | CL2021003169A1 (enExample) |
| EA (1) | EA202193296A1 (enExample) |
| IL (1) | IL288398A (enExample) |
| MX (2) | MX2021014465A (enExample) |
| SG (1) | SG11202113112WA (enExample) |
| TW (1) | TW202111124A (enExample) |
| UY (1) | UY38733A (enExample) |
| WO (1) | WO2020243702A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230374522A1 (en) * | 2022-04-15 | 2023-11-23 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for modulating scap activity |
| US20250313834A1 (en) * | 2022-05-25 | 2025-10-09 | Amgen Inc. | Rnai constructs for inhibiting scap expression and methods of use thereof |
| EP4555088A1 (en) * | 2022-07-11 | 2025-05-21 | Sanegene Bio USA Inc. | Optimized 2'- modified ribose derivatives and methods of use |
| CN120322552A (zh) * | 2022-07-27 | 2025-07-15 | e-生物有限公司 | 核酸化合物 |
| WO2024104416A1 (zh) * | 2022-11-17 | 2024-05-23 | 北京福元医药股份有限公司 | 抑制SCAP基因表达的siRNA、其缀合物和药物组合物及用途 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| US5714331A (en) | 1991-05-24 | 1998-02-03 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
| US5719262A (en) | 1993-11-22 | 1998-02-17 | Buchardt, Deceased; Ole | Peptide nucleic acids having amino acid side chains |
| US5539082A (en) | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
| CA2124087C (en) | 1991-11-22 | 2002-10-01 | James L. Winkler | Combinatorial strategies for polymer synthesis |
| US5981505A (en) | 1993-01-26 | 1999-11-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods for delivery of genetic material |
| US5837533A (en) | 1994-09-28 | 1998-11-17 | American Home Products Corporation | Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent |
| US5556752A (en) | 1994-10-24 | 1996-09-17 | Affymetrix, Inc. | Surface-bound, unimolecular, double-stranded DNA |
| US5840710A (en) | 1994-12-09 | 1998-11-24 | Genzyme Corporation | Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules |
| US5976567A (en) | 1995-06-07 | 1999-11-02 | Inex Pharmaceuticals Corp. | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| US5981501A (en) | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
| US5545531A (en) | 1995-06-07 | 1996-08-13 | Affymax Technologies N.V. | Methods for making a device for concurrently processing multiple biological chip assays |
| US7422902B1 (en) | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| US5854033A (en) | 1995-11-21 | 1998-12-29 | Yale University | Rolling circle replication reporter systems |
| US6217900B1 (en) | 1997-04-30 | 2001-04-17 | American Home Products Corporation | Vesicular complexes and methods of making and using the same |
| CA2294988C (en) | 1997-07-01 | 2015-11-24 | Isis Pharmaceuticals Inc. | Compositions and methods for the delivery of oligonucleotides via the alimentary canal |
| AU747597B2 (en) | 1998-07-20 | 2002-05-16 | Inex Pharmaceuticals Corporation | Liposomal encapsulated nucleic acid-complexes |
| US7833992B2 (en) | 2001-05-18 | 2010-11-16 | Merck Sharpe & Dohme | Conjugates and compositions for cellular delivery |
| US7491805B2 (en) | 2001-05-18 | 2009-02-17 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
| US6693187B1 (en) | 2000-10-17 | 2004-02-17 | Lievre Cornu Llc | Phosphinoamidite carboxlates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge |
| US7109165B2 (en) | 2001-05-18 | 2006-09-19 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
| US20030130186A1 (en) | 2001-07-20 | 2003-07-10 | Chandra Vargeese | Conjugates and compositions for cellular delivery |
| US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| CA2487274A1 (en) | 2002-05-06 | 2003-11-13 | Nucleonics Inc. | Spermine chemically linked to lipids and cell-specific targeting molecules as a transfection agent |
| US8017762B2 (en) | 2003-04-17 | 2011-09-13 | Alnylam Pharmaceuticals, Inc. | Modified iRNA agents |
| US7723509B2 (en) | 2003-04-17 | 2010-05-25 | Alnylam Pharmaceuticals | IRNA agents with biocleavable tethers |
| ES2702942T3 (es) | 2003-04-17 | 2019-03-06 | Alnylam Pharmaceuticals Inc | Agentes de ARNi modificados |
| US7851615B2 (en) | 2003-04-17 | 2010-12-14 | Alnylam Pharmaceuticals, Inc. | Lipophilic conjugated iRNA agents |
| AU2007297388A1 (en) | 2006-09-18 | 2008-03-27 | Alnylam Pharmaceuticals, Inc. | RNAi modulation of scap and therapeutic uses thereof |
| CA2685127C (en) | 2007-04-23 | 2019-01-08 | Alnylam Pharmaceuticals, Inc. | Glycoconjugates of rna interference agents |
| WO2009073809A2 (en) | 2007-12-04 | 2009-06-11 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
| AR090905A1 (es) | 2012-05-02 | 2014-12-17 | Merck Sharp & Dohme | Conjugados que contienen tetragalnac y peptidos y procedimientos para la administracion de oligonucleotidos, composicion farmaceutica |
| EP3564374A1 (en) | 2013-06-21 | 2019-11-06 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulation of target nucleic acids |
| IL316808A (en) * | 2014-08-20 | 2025-01-01 | Alnylam Pharmaceuticals Inc | Modified double-stranded RNA materials and their uses |
| EP3387129A1 (en) | 2015-12-10 | 2018-10-17 | Alnylam Pharmaceuticals, Inc. | STEROL REGULATORY ELEMENT BINDING PROTEIN (SREBP) CHAPERONE (SCAP) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
| UY37376A (es) * | 2016-08-26 | 2018-03-23 | Amgen Inc | Construcciones de arni para inhibir expresión de asgr1 y métodos para su uso |
| CN110268060B (zh) * | 2017-01-10 | 2024-07-26 | 箭头药业股份有限公司 | α-1抗胰蛋白酶(AAT)RNAi物质、包含AAT RNAi物质的组合物和使用方法 |
-
2020
- 2020-06-01 CA CA3141902A patent/CA3141902A1/en active Pending
- 2020-06-01 EP EP20746771.3A patent/EP3976786A2/en active Pending
- 2020-06-01 UY UY0001038733A patent/UY38733A/es not_active Application Discontinuation
- 2020-06-01 US US17/615,520 patent/US20220307022A1/en active Pending
- 2020-06-01 TW TW109118339A patent/TW202111124A/zh unknown
- 2020-06-01 AR ARP200101545A patent/AR119061A1/es unknown
- 2020-06-01 EA EA202193296A patent/EA202193296A1/ru unknown
- 2020-06-01 BR BR112021024080A patent/BR112021024080A2/pt unknown
- 2020-06-01 CN CN202080041291.2A patent/CN113924368B/zh active Active
- 2020-06-01 JP JP2021570170A patent/JP7763104B2/ja active Active
- 2020-06-01 AU AU2020284254A patent/AU2020284254A1/en active Pending
- 2020-06-01 MX MX2021014465A patent/MX2021014465A/es unknown
- 2020-06-01 SG SG11202113112WA patent/SG11202113112WA/en unknown
- 2020-06-01 CN CN202510074363.8A patent/CN119842815A/zh active Pending
- 2020-06-01 WO PCT/US2020/035545 patent/WO2020243702A2/en not_active Ceased
- 2020-06-01 KR KR1020217042450A patent/KR20220016138A/ko active Pending
-
2021
- 2021-11-25 IL IL288398A patent/IL288398A/en unknown
- 2021-11-25 MX MX2026000159A patent/MX2026000159A/es unknown
- 2021-11-29 CL CL2021003169A patent/CL2021003169A1/es unknown
-
2025
- 2025-01-22 CL CL2025000194A patent/CL2025000194A1/es unknown
- 2025-10-20 JP JP2025176137A patent/JP2026016500A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022534402A5 (enExample) | ||
| US11591598B2 (en) | Oligomers and oligomer conjugates | |
| JP2023537943A5 (enExample) | ||
| JP2023103244A5 (enExample) | ||
| JP2021506238A5 (enExample) | ||
| JP2022501040A5 (enExample) | ||
| JP4718379B2 (ja) | 修飾された低分子干渉ｒｎａ分子および使用方法 | |
| CN105377887B (zh) | 用于调节载脂蛋白(a)表达的组合物和方法 | |
| JP6492053B2 (ja) | 修飾ｔｇｆ−ベータオリゴヌクレオチド | |
| JP2022511550A5 (enExample) | ||
| JP2024105284A5 (enExample) | ||
| TWI881004B (zh) | 用於治療ｈｂｖ之靶向ｈｂｖ的治療性寡核苷酸及ｔｌｒ７促效劑之醫藥組合 | |
| JP2017512502A (ja) | 新規の二重らせんオリゴｒｎａおよびこれを含む線維症または呼吸器疾患の予防または治療用薬学組成物 | |
| JP2019524151A5 (enExample) | ||
| CN111378655A (zh) | 抑制CTGF基因表达的siRNA、含有该siRNA的药物组合物及其用途 | |
| JP2024538859A5 (enExample) | ||
| JP2024512635A5 (enExample) | ||
| JP2015532100A (ja) | アンフィレギュリンに特異的な二重鎖オリゴｒｎａ、そのような二重鎖オリゴｒｎａを含む二重鎖オリゴｒｎａの構造体及びこれを含む呼吸器疾患の予防または治療用の組成物 | |
| EP4063504A1 (en) | Ctgf gene-specific double-stranded oligonucleotide, and a composition for preventing and treating fibrotic diseases and respiratory-related diseases comprising same | |
| JP2025512771A5 (enExample) | ||
| WO2023213284A1 (zh) | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 | |
| JP2024543195A5 (enExample) | ||
| JP2024539097A5 (enExample) | ||
| WO2024141031A1 (zh) | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 | |
| WO2023116764A1 (zh) | 一种核酸、含有该核酸的组合物与缀合物及其用途 |